Compounds with affinity and selectivity of helatoobrazutee with elements of the first transition series and their use in therapy and diagnosis

 

The invention relates to medicine. The described method of inhibiting the growth of bacterial and fungal cells on the surface or in solution, comprising the complexing agents of formula Iwhere p, q, r, R1, R2, R3and R4have the meanings indicated in the claims, while the molecular weight of the specified complexing agents does not exceed 2000 with affinity and selectivity of helatoobrazutee with elements of the first transition series. The introduction of free or associated connection or physiological salt free or associated connection leads to reduced bioavailability of the elements of the first transition series of in vivo and/or removal from the body elements of the first transition series of elements with similar chemical properties. These characteristics make such compounds applicable in the treatment of diseases associated with excess body elements of the first transition series and elements with similar chemical properties. The invention demonstrates that such compounds inhibit cell division mammalian, bacterial and fungal cells and, thus, are applicable for the treatment of neoplastic, infectious, in the logical availability of tissue in vivo, and they are applicable in the treatment of tissue damage mediated by free radicals and tissue damage mediated by oxidative processes. When the Association prior to the introduction in complex with radioactive cations or exhibiting paramagnetic properties of elements of first transition series elements or possessing chemical properties, similar to those elements of the first transition series, the resulting complexes are applicable as diagnostic tools in the field of nuclear medicine and magnetic resonance imaging (MSV). 10 C. and 37 C.p. f-crystals.

Description text in facsimile form (see graphic part). Ty

Claims

1. Method of inhibiting the growth of bacterial and fungal cells on the surface or in solution, including the introduction of a given surface or in the specified solution of complexing agents having the formulawhere each of p and q independently represents an integer from 2 to 3; r represents an integer 1 or 2; each R2, R3and R4independently selected from the group comprising H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenone, alkanity, Ara, alkyl interrupted TIA, alkenyl interrupted TIA, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkyl, aminoaryl, aminoalkyl, hydroxyalkyl, hydroxyalkyl, hydroxyaryl, hydroxyarylalkyl, their halogen-substituted derivatives; R1selected from the group comprising R2, R3and R4and radicals of the formula
where each of R41, R42and R43independently selected from the group comprising H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenone, alkanity, aryloxy, aaltio, alkyl interrupted by one or more oxa, alkenyl interrupted by one or more oxa, alkyl interrupted TIA, alkenyl interrupted TIA, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkyl, aminoaryl, aminoalkyl, hydroxyalkyl, hydroxyalkyl, hydroxyaryl, hydroxyarylalkyl and their halogen-substituted derivatives;
R44selected from the group comprising H, hydroxy, amino, alkyl, alkyl interrupted oxa, alkoxy, aryl, aryloxyalkyl, alkoxyaryl and their halogen-substituted derivatives;
n = 0 or 1;
X is selected from the group comprising alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenone, aryloxy, aaltio, alkyl interrupted by one or more oxa, al alkoxyaryl, aminoalkyl, aminoalkyl, aminoaryl, aminoalkyl, hydroxyalkyl, hydroxyalkyl, hydroxyaryl, hydroxyarylalkyl, halogen-substituted derivatives of each of the above substituents and radicals selected from the group including



-OR46

-S-R46
-CHO









where each of R41, R42, R43and R44independently represents the above-described substituents;
each of R46and R47independently selected from the group comprising H, alkyl and aryl, or taken together, they form a ring structure;
each of R48and R49independently represents H, alkyl, aryl, alkoxy, alkyl interrupted by one or more oxa, aryloxyalkyl, alkoxyaryl and their halogen-substituted derivatives;
each of R50, R51enyloxy, alkanity, aryloxy, aaltio, aminoalkyl, aminoalkyl, aminoaryl, aminoalkyl, hydroxyalkyl, hydroxyalkyl, hydroxyaryl and hydroxyarylalkyl;
m is an integer from 1 to 3;
and where, optionally, any two of R1, R2, R3and R4merged to form a ring structure;
and their dimers, where these dimers formed by covalent attachment of the two complexing agents of formula (I) via a linking group containing from 1 to 6 carbon atoms; and their physiological salts, provided that the molecular weight of the specified complexing agents does not exceed 2000.

2. The method according to p. 1, where the specified surface is the surface of the body.

3. The method according to p. 1, where the specified complexing agents added to the solution.

4. A method of treatment of conditions that depend on the biological availability of the elements of the first transition series of the patient, including the introduction of a specified patient an effective amount of complexing agents having the formula

where each of p and q independently represents an integer from 2 to 3;
r represents an integer 1 or 2;
each of R2, R3and R4Diltia, aryloxy, aaltio, alkyl interrupted by one or more oxa, alkenyl interrupted by one or more oxa, alkyl interrupted TIA, alkenyl interrupted TIA, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkyl, aminoaryl, aminoalkyl, hydroxyalkyl, hydroxyalkyl, hydroxyaryl, hydroxyarylalkyl, their halogen-substituted derivatives;
R1selected from the group comprising R2, R3and R4and radicals of the formula

where each of R41, R42and R43independently selected from the group comprising H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenone, alkanity, aryloxy, aaltio, alkyl interrupted by one or more oxa, alkenyl interrupted by one or more oxa, alkyl interrupted TIA, alkenyl interrupted TIA, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkyl, aminoaryl, aminoalkyl, hydroxyalkyl, hydroxyalkyl, hydroxyaryl, hydroxyarylalkyl and their halogen-substituted derivatives;
R44selected from the group comprising H, hydroxy, amino, alkyl, alkyl interrupted oxa, alkoxy, aryl, aryloxyalkyl, alkoxyaryl and their halogen-substituted derivatives;
n = 0 or 1;
X is selected from the group comprising alkyl, Kimi oxa, alkenyl interrupted by one or more oxa, alkyl interrupted by one or more TIA, alkenyl interrupted by one or more TIA, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkyl, aminoaryl, aminoalkyl, hydroxyalkyl, hydroxyalkyl, hydroxyaryl, hydroxyarylalkyl, halogen-substituted derivatives of each of the above and the radicals selected from the group including



OR46

-S-R46
-CHO









where each of R41, R42, R43and R44independently represents the above-described substituents;
each of R46and R47independently selected from the group comprising H, alkyl and aryl, or taken together, they form a ring structure;
each of R48and R49independently represents H, alkyl, ar derivative;
each of R50, R51and R52independently selected from the group comprising H, alkyl, alkenyl, aryl, arylalkyl, alkyloxy, alkylthio, alkenylacyl, alkanity, aryloxy, aaltio, aminoalkyl, aminoalkyl, aminoaryl, aminoalkyl, hydroxyalkyl, hydroxyalkyl, hydroxyaryl and hydroxyarylalkyl;
m is an integer from 1 to 3;
and where, optionally, any two of R1, R2, R3and R4merged to form a ring structure;
and their dimers, where these dimers formed by covalent attachment of the two complexing agents of formula (I) via a linking group containing from 1 to 6 carbon atoms; and their physiological salts, provided that the molecular weight of the specified complexing agents does not exceed 2000; and the complexing agents is in a pharmaceutically acceptable carrier.

5. A method of treating conditions associated with elevated levels of elements of the first transition series of the patient, including the introduction of a specified patient an effective amount of complexing agents having the formula

where each of p and q independently represents an integer from 2 to 3;
r pruchya N, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenone, alkanity, aryloxy, aaltio, alkyl interrupted by one or more oxa, alkenyl interrupted by one or more oxa, alkyl interrupted TIA, alkenyl interrupted TIA, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkyl, aminoaryl, aminoalkyl, hydroxyalkyl, hydroxyalkyl, hydroxyaryl, hydroxyarylalkyl, their halogen-substituted derivatives;
R1selected from the group comprising R2, R3and R4and radicals of the formula

where each of R41, R42and R43independently selected from the group comprising H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenone, alkanity, aryloxy, aaltio, alkyl interrupted by one or more oxa, alkenyl interrupted by one or more oxa, alkyl interrupted TIA, alkenyl interrupted TIA, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkyl, aminoaryl, aminoalkyl, hydroxyalkyl, hydroxyalkyl, hydroxyaryl, hydroxyarylalkyl and their halogen-substituted derivatives;
R44selected from the group comprising H, hydroxy, amino, alkyl, alkyl interrupted oxa, alkoxy, aryl, aryloxyalkyl, alkoxyaryl and their halogenated is ylthio, alkenone, aryloxy, aaltio, alkyl interrupted by one or more oxa, alkenyl interrupted by one or more oxa, alkyl interrupted by one or more TIA, alkenyl interrupted by one or more than one TIA, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkyl, aminoaryl, aminoalkyl, hydroxyalkyl, hydroxyalkyl, hydroxyaryl, hydroxyarylalkyl, halogen-substituted derivatives of each of the above and the radicals selected from the group including



-OR46

-S-R46
-CHO









where each of R41, R42, R43and R44independently represents the above-described substituents;
each of R46and R47independently selected from the group comprising H, alkyl and aryl, or taken together, they form ring structures the KSA, aryloxyalkyl, alkoxyaryl and their halogen-substituted derivatives;
each of R50, R51and R52independently selected from the group comprising H, alkyl, alkenyl, aryl, arylalkyl, alkyloxy, alkylthio, alkenylacyl, alkanity, aryloxy, aaltio, aminoalkyl, aminoalkyl, aminoaryl, aminoalkyl, hydroxyalkyl, hydroxyalkyl, hydroxyaryl and hydroxyarylalkyl;
m is an integer from 1 to 3;
and where, optionally, any two of R1, R2, R3and R4merged to form a ring structure;
and their dimers, where these dimers formed by covalent attachment of the two complexing agents of formula (I) via a linking group containing from 1 to 6 carbon atoms; and their physiological salts, provided that the molecular weight of the specified complexing agents does not exceed 2000; and the complexing agents is in a pharmaceutically acceptable carrier.

6. The method according to p. 4, where the above condition mediated reproduction of DNA or RNA viruses.

7. The method according to p. 4, where the above condition mediated cell proliferation.

8. The method according to p. 7, where the specified condition is a neoplastic disease.

9. The method according to p. 7, where MC is the first condition is an infectious disease, caused by fungi.

11. The method according to p. 7, where the specified condition is an infectious disease caused by protozoa.

12. The method according to p. 7, where the specified condition is an inflammatory condition.

13. The method according to p. 7, where the specified condition is an immune disorder.

14. The method according to p. 7, where the specified condition is abortion.

15. The method according to p. 7, where the specified condition is further mediated by the proliferation of osteoclasts.

16. The method according to p. 4, where the above condition mediated tissue destruction by free-radical or oxidative mechanism.

17. The method according to p. 16, where said conditions selected from the group comprising rheumatoid arthritis and related diseases.

18. The method according to p. 5, where the above condition is selected from the group including hemachromatosis, hemosiderosis and Wilson's disease.

19. The method according to PP.1, 4, or 5, where at least two of the above R1selected from the group comprising the radicals containing phosphonic acid radicals containing complex monoether phosphonic acid radicals containing carboxylic acid, and a combination thereof.

20. Pharmaceutical composition for treating physiological conditions, sovietinei formula

where each of p and q independently represents an integer from 2 to 3;
r represents an integer 1 or 2;
each of R2, R3and R4independently selected from the group comprising H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenone, alkanity, aryloxy, aaltio, alkyl interrupted by one or more oxa, alkenyl interrupted by one or more oxa, alkyl interrupted TIA, alkenyl interrupted TIA, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkyl, aminoaryl, aminoalkyl, hydroxyalkyl, hydroxyalkyl, hydroxyaryl, hydroxyarylalkyl, their halogen-substituted derivatives;
R1selected from the group comprising R2, R3and R4and radicals of the formula

where each of R41, R42and R43independently selected from the group comprising H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenone, alkanity, aryloxy, aaltio, alkyl interrupted by one or more oxa, alkenyl interrupted by one or more oxa, alkyl interrupted TIA, alkenyl interrupted TIA, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkyl, aminoaryl, aminoalkyl, hydroxyalkyl, hydroxy, including H, hydroxy, amino, alkyl, alkyl interrupted oxa, alkoxy, aryl, aryloxyalkyl, alkoxyaryl and their halogen-substituted derivatives;
n = 0 or 1;
X is selected from the group comprising alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenone, aryloxy, aaltio, alkyl interrupted by one or more oxa, alkenyl interrupted by one or more oxa, alkyl interrupted TIA, alkenyl interrupted TIA, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkyl, aminoaryl, aminoalkyl, hydroxyalkyl, hydroxyalkyl, hydroxyaryl, hydroxyarylalkyl, halogen-substituted derivatives of each of the above and the radicals selected from the group including



-OR46

-S-R46
-CHO









where each of R41, R42, R43and R44nezaviduyu, comprising H, alkyl and aryl, or taken together, they form a ring structure;
each of R48and R49independently represents H, alkyl, aryl, alkoxy, alkyl interrupted by one or more oxa, aryloxyalkyl, alkoxyaryl and their halogen-substituted derivatives;
each of R50, R51and R52independently selected from the group comprising H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenylacyl, alkanity, aryloxy, aaltio, aminoalkyl, aminoalkyl, aminoaryl, aminoalkyl, hydroxyalkyl, hydroxyalkyl, hydroxyaryl and hydroxyarylalkyl;
m is an integer from 1 to 3;
and where, optionally, any two of R1, R2, R3and R4merged to form a ring structure; and their dimers, where these dimers formed by covalent attachment of the two compounds of the formula (I) via a linking group containing from 1 to 6 carbon atoms; and their physiological salts, provided that the molecular weight of the specified connection does not exceed 2000; in a pharmaceutically acceptable carrier.

21. Compounds having the formula

where each of p and q independently represents an integer from 2 to 3;
R1selected from the group comprising R2, R3, R4except for N, and radicals of the formula

where each of R41, R42and R43independently selected from the group comprising H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenone, alkanity, aryloxy, aaltio, alkyl interrupted by one or more oxa, alkenyl interrupted by one or more oxa, alkyl interrupted TIA, alkenyl interrupted TIA, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkyl, aminoaryl, aminoalkyl, hydroxyalkyl, hydroxyalkyl, hydroxyaryl, hydroxyarylalkyl and their halogen-substituted derivatives;
R44selected from the group comprising H, hydroxy, amino, alkyl, alkyl interrupted oxa, alkoxy, aryl, aryloxyalkyl, the l, aryl, arylalkyl, alkoxy, alkylthio, alkenone, aryloxy, aaltio,
alkyl interrupted by one or more oxa, alkenyl interrupted by one or more oxa, alkyl interrupted TIA, alkenyl interrupted TIA, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkyl, aminoaryl, aminoalkyl, hydroxyalkyl, hydroxyalkyl, hydroxyaryl, hydroxyarylalkyl, halogen-substituted derivatives of each of the above and the radicals selected from the group including



-OR46

-S-R46
-CHO









where each of R41, R42, R43and R44independently represents the above-described substituents;
each of R46and R47independently selected from the group comprising H, alkyl and aryl, or taken together, they form a ring structure;
to the several oxa, aryloxyalkyl, alkoxyaryl and their halogen-substituted derivatives;
each of R50, R51and R52independently selected from the group comprising H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenylacyl, alkanity, aryloxy, aaltio, aminoalkyl, aminoalkyl, aminoaryl, aminoalkyl, hydroxyalkyl, hydroxyalkyl, hydroxyaryl and hydroxyarylalkyl;
m is an integer from 1 to 3;
and where at least two of the above R1and R4groups contain two adjacent carbon atom directly attached to the nitrogen atoms, the carbon atom in positionrelative to the nitrogen atom is substituted by hydroxy and at least one member selected from the group comprising hydroxymethyl, alkoxymethyl, arcenciel, relaxometer and combination thereof; and where, optionally, any two of R1, R2, R3and R4merged to form a ring structure;
and their dimers, where these dimers formed by covalent attachment of the two compounds of the formula (I) via a linking group containing from 1 to 6 carbon atoms; and their physiological salts, provided that the molecular weight of the specified connection does not exceed 2000.

22. Method of inhibiting the growth of bacteria or fungi on the surface or in solution, includes printed on the specified surface or in the specified solution of complexing agents having the formula

where each of t, u and v independently equal to from 2 to 3;
w is an integer from 1 to 4;
each of R12and R13independently selected from the group comprising H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenone, alkanity, aryloxy, aaltio, alkyl interrupted by one or more oxa, alkenyl interrupted by one or more oxa, alkyl interrupted TIA, alkenyl interrupted TIA, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkyl, aminoaryl, aminoalkyl, hydroxyalkyl, hydroxyalkyl, hydroxyaryl, hydroxyarylalkyl, their halogen-substituted derivatives;
R11selected from the group comprising R12and R13and radicals of the formula

where each of R41, R42and R43independently selected from the group comprising H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenone, alkanity, aryloxy, aaltio, alkyl interrupted by one or more oxa, alkenyl interrupted by one or more oxa, alkyl interrupted TIA, alkenyl interrupted TIA, aryloxyalkyl, alkoxycarbonyl and their halogen-substituted derivatives;
R44selected from the group comprising H, hydroxy, amino, alkyl, alkyl interrupted oxa, alkoxy, aryl, aryloxyalkyl, alkoxyaryl and their halogen-substituted derivatives;
n = 0 or 1;
X is selected from the group comprising alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenone, aryloxy, aaltio, alkyl interrupted by one or more oxa, alkenyl interrupted by one or more oxa, alkyl interrupted TIA, alkenyl interrupted TIA, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkyl, aminoaryl, aminoalkyl, hydroxyalkyl, hydroxyalkyl, hydroxyaryl, hydroxyarylalkyl, halogen-substituted derivatives of each of the above and the radicals selected from the group including



-OR46

-S-R46
-CHO









where each of R41, R42, R independently selected from the group comprising H, alkyl and aryl, or taken together, they form a divalent linking group between the atoms to which they are attached, thus forming a ring structure;
each of R48and R49independently selected from the group comprising H, alkyl, aryl, alkoxy, alkyl interrupted by one or more oxa, aryloxyalkyl, alkoxyaryl and their halogen-substituted derivatives;
each of R50, R51and R52independently selected from the group comprising H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenylacyl, alkanity, aryloxy, aaltio, aminoalkyl, aminoalkyl, aminoaryl, aminoalkyl, hydroxyalkyl, hydroxyalkyl, hydroxyaryl and hydroxyarylalkyl;
m is an integer from 1 to 3;
and where, optionally, any two of R1, R2, R3and R4merged to form a ring structure;
and their dimers, where these dimers formed by covalent attachment of the two compounds of the formula (I) via a linking group containing from 1 to 6 carbon atoms; and their physiological salts, provided that the molecular weight of the specified complexing agents does not exceed 2000.

24. The method according to p. 23, where the decree of the tel is added to the solution.

26. A method of treatment of conditions that depend on the biological availability of the elements of the first transition series of the patient, including the introduction of a specified patient an effective amount of complexing agents having the formula

where each of t, u and v independently equal to from 2 to 3;
w is an integer from 1 to 4;
each of R12and R13independently selected from the group comprising H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenone, alkanity, aryloxy, aaltio, alkyl interrupted by one or more oxa, alkenyl interrupted by one or more oxa, alkyl interrupted TIA, alkenyl interrupted TIA, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkyl, aminoaryl, aminoalkyl, hydroxyalkyl, hydroxyalkyl, hydroxyaryl, hydroxyarylalkyl, their halogen-substituted derivatives;
R11selected from the group comprising R12and R13and radicals of the formula

where each of R41, R42and R43independently selected from the group comprising H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenone, alkanity, aryloxy, aaltio, alkyl interrupted by one or more oxa, alkenyl searil, aminoalkyl, aminoalkyl, aminoaryl aminoalkyl, hydroxyalkyl, hydroxyalkyl, hydroxyaryl hydroxyarylalkyl and their halogen-substituted derivatives;
R44selected from the group comprising H, hydroxy, amino, alkyl, alkyl interrupted oxa, alkoxy, aryl, aryloxyalkyl, alkoxyaryl and their halogen-substituted derivatives;
n = 0 or 1;
X is selected from the group comprising alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenone, aryloxy, aaltio, alkyl interrupted by one or more oxa, alkenyl interrupted by one or more oxa, alkyl interrupted TIA,
alkenyl interrupted TIA, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkyl, aminoaryl, aminoalkyl, hydroxyalkyl, hydroxyalkyl, hydroxyaryl, hydroxyarylalkyl, halogen-substituted derivatives of each of the above substituents and radicals selected from the group including



OR46

-S-R46
-CHO





where each of R41, R42, R43and R44independently represents the above-described substituents;
each of R46and R47independently selected from the group comprising H, alkyl or aryl or all of them together forming a divalent linking group between the atoms to which they are attached, thus forming a ring structure;
each of R48and R49independently selected from the group comprising H, alkyl, aryl, alkoxy, alkyl interrupted by one or more oxa, aryloxyalkyl, alkoxyaryl and their halogen-substituted derivatives;
each of R50, R51and R52independently selected from the group comprising H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenylacyl, alkanity, aryloxy, aaltio, aminoalkyl, aminoalkyl, aminoaryl, aminoalkyl, hydroxyalkyl, hydroxyalkyl, hydroxyaryl and hydroxyarylalkyl;
m is an integer from 1 to 3;
and where, optionally, any two of R1, R2, R3and R4merged to form a ring structure;
and their dimers, where these dimers formed by covalent attachment of the two complexing agents of formula (I) via a linking group, steevee 2000.

27. A method of treating conditions associated with elevated levels of elements of the first transition series of the patient, including the introduction of a specified patient an effective amount of complexing agents having the formula

where each of t, u and v independently equal to from 2 to 3;
w is an integer from 1 to 4;
each of R12and R13independently selected from the group comprising H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenone, alkanity, aryloxy, aaltio, alkyl interrupted by one or more oxa, alkenyl interrupted by one or more oxa, alkyl interrupted TIA, alkenyl interrupted TIA, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkyl, aminoaryl, aminoalkyl, hydroxyalkyl, hydroxyalkyl, hydroxyaryl, hydroxyarylalkyl, their halogen-substituted derivatives;
R11selected from the group comprising R12and R13and radicals of the formula

where each of R41, R42and R43independently selected from the group comprising H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenone, alkanity, aryloxy, aaltio, alkyl interrupted by one or more oxa, al is alkoxyaryl, aminoalkyl, aminoalkyl, aminoaryl, aminoalkyl, hydroxyalkyl, hydroxyalkyl, hydroxyaryl, hydroxyarylalkyl and their halogen-substituted derivatives;
R44selected from the group comprising H, hydroxy, amino, alkyl, alkyl interrupted oxa, alkoxy, aryl, aryloxyalkyl, alkoxyaryl and their halogen-substituted derivatives;
n = 0 or 1;
X is selected from the group comprising alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenone, aryloxy, aaltio, alkyl interrupted by one or more oxa, alkenyl interrupted by one or more oxa, alkyl interrupted TIA, alkenyl interrupted TIA, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkyl, aminoaryl, aminoalkyl, hydroxyalkyl, hydroxyalkyl, hydroxyaryl, hydroxyarylalkyl, halogen-substituted derivatives of each of the above and the radicals selected from the group including



OR46

-S-R46
-CHO






where each of R41, R42, R43and R44independently represents the above-described substituents;
each of R46and R47independently selected from the group comprising H, alkyl and aryl, or taken together, they form a divalent linking group between the atoms to which they are attached, thus forming a ring structure;
each of R48and R49independently selected from the group comprising H, alkyl, aryl, alkoxy, alkyl interrupted by one or more oxa, aryloxyalkyl, alkoxyaryl and their halogen-substituted derivatives;
each of R50, R51and R52independently selected from the group comprising H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenylacyl, alkanity, aryloxy, aaltio, aminoalkyl, aminoalkyl, aminoaryl, aminoalkyl, hydroxyalkyl, hydroxyalkyl, hydroxyaryl and hydroxyarylalkyl;
m is an integer from 1 to 3;
and where, optionally, any two of R1, R2, R3and R4merged to form a ring structure;
and their dimers, where these dimers formed by covalent attachment of the two complexing agents of formula (I) via a linking group containing 000.

28. The method according to p. 26, where the specified condition mediated reproduction of DNA or RNA viruses.

29. The method according to p. 26, where the specified condition mediated cell proliferation.

30. The method according to p. 29, where the specified condition is a neoplastic disease.

31. The method according to p. 29, where the specified condition is an infectious disease caused by bacteria.

32. The method according to p. 29, where the specified condition is an infectious disease caused by fungi.

33. The method according to p. 29, where the specified condition is an infectious disease caused by protozoa.

34. The method according to p. 29, where the specified condition is an inflammatory condition.

35. The method according to p. 29, where the specified condition is an immune disorder.

36. The method according to p. 29, where the specified condition is abortion.

37. The method according to p. 29, where the specified condition is further mediated by the proliferation of osteoclasts.

38. The method according to p. 26, where the specified condition mediated tissue destruction by free-radical or oxidative mechanism.

39. The method according to p. 38, where said conditions selected from the group comprising rheumatoid arthritis and related diseases.

40. The method according to 41. The method according to PP.23, 26 or 27, where each of t, and v = 2 and w = 1.

42. The method according to p. 41, where at least two of these1selected from the group comprising the radicals containing phosphonic acid radicals containing complex monoether phosphonic acid radicals containing carboxylic acid and a combination thereof.

43. The method according to PP.23, 26 or 27, where each of t, u, and v = 2 and w = 2.

44. The method according to PP.43, where at least two of the above R1selected from the group comprising the radicals containing phosphonic acid radicals containing complex monoether phosphonic acid radicals containing carboxylic acid and a combination thereof.

45. Pharmaceutical composition for treating a physiological States, depending on the biological availability of the elements of the first transition series, containing an effective amount of the compounds of formula

where each of t, u and v independently equal to from 2 to 3;
w is an integer from 1 to 4;
each of R12and R13independently selected from the group comprising H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenone, alkanity, aryloxy, aaltio, alkyl interrupted by one or more oxa, alkenyl interrupted by one or more of canil, aminoaryl, aminoalkyl, hydroxyalkyl, hydroxyalkyl, hydroxyaryl, hydroxyarylalkyl, their halogen-substituted derivatives;
R11selected from the group comprising R12and R13and radicals of the formula

where each of R41, R42and R43independently selected from the group comprising H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenone, alkanity, aryloxy, aaltio, alkyl interrupted by one or more oxa, alkenyl interrupted by one or more oxa, alkyl interrupted TIA, alkenyl interrupted TIA, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkyl, aminoaryl, aminoalkyl, hydroxyalkyl, hydroxyalkyl, hydroxyaryl, hydroxyarylalkyl and their halogen-substituted derivatives;
R44selected from the group comprising H, hydroxy, amino, alkyl, alkyl interrupted oxa, alkoxy, aryl, aryloxyalkyl, alkoxyaryl and their halogen-substituted derivatives;
n = 0 or 1; and
X is selected from the group comprising alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenone, aryloxy, aaltio, alkyl interrupted by one or more oxa, alkenyl interrupted by one or more oxa, alkyl interrupted TIA, alkenyl interrupted TIA, arylamidoximes, hydroxyarylalkyl, halogen-substituted derivatives of each of the above substituents and radicals selected from the group including



-OR46

-S-R46
-CHO









where each of R41, R42, R43and R44independently represents the above-described substituents;
each of R46and R47independently selected from the group comprising H, alkyl and aryl, or taken together, they form a divalent linking group between the atoms to which they are attached, thus forming a ring structure;
each of R48and R49independently selected from the group comprising H, alkyl, aryl, alkoxy, alkyl interrupted by one or more oxa, aryloxyalkyl, alkoxyaryl and their halogen-substituted derivatives;
each of R50ltio, alkenylacyl, alkanity, aryloxy, aaltio, aminoalkyl, aminoalkyl, aminoaryl, aminoalkyl, hydroxyalkyl, hydroxyalkyl, hydroxyaryl and hydroxyarylalkyl;
m is an integer from 1 to 3;
and where, optionally, any two of R1, R2, R3and R4merged to form a ring structure;
and their dimers, where these dimers formed by covalent attachment of the two compounds of the formula (I) via a linking group containing from 1 to 6 carbon atoms; and their physiological salts, provided that the molecular weight of the specified connection does not exceed 2000; and a pharmaceutically acceptable carrier.

46. The compounds of formula

where each of t, u and v independently equal to from 2 to 3;
w is an integer from 1 to 4;
each of R12and R13independently selected from the group comprising H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenone, alkanity, aryloxy, aaltio, alkyl interrupted by one or more oxa, alkenyl interrupted by one or more oxa, alkyl interrupted TIA, alkenyl interrupted TIA, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkyl, aminoaryl, aminoalkyl, hydroxyn from the group includes R12, R13except for N, and radicals of the formula

where each of R41, R42and R43independently selected from the group comprising H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenone, alkanity, aryloxy, aaltio, alkyl interrupted by one or more oxa, alkenyl interrupted by one or more oxa, alkyl interrupted TIA, alkenyl interrupted TIA, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkyl, aminoaryl, aminoalkyl, hydroxyalkyl, hydroxyalkyl, hydroxyaryl, hydroxyarylalkyl and their halogen-substituted derivatives;
R44selected from the group comprising H, hydroxy, amino, alkyl, alkyl interrupted oxa, alkoxy, aryl, aryloxyalkyl, alkoxyaryl and their halogen-substituted derivatives;
n = 0 or 1;
X is selected from the group comprising alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenone, aryloxy, aaltio, alkyl interrupted by one or more oxa, alkenyl interrupted by one or more oxa, alkyl interrupted TIA, alkenyl interrupted TIA, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkyl, aminoaryl, aminoalkyl hydroxyalkyl, hydroxyalkyl, hydroxyaryl, hydroxyarylalkyl, �p://img.russianpatents.com/img_data/57/577127.gif">


-OR46

-S-R46
-CHO









where each of R41, R42, R43and R44independently represents the above-described substituents;
each of R46and R47independently selected from the group comprising H, alkyl and aryl, or taken together, they form a divalent linking group between the atoms to which they are attached, thus forming a ring structure;
each of R48and R49independently selected from the group comprising H, alkyl, aryl, alkoxy, alkyl interrupted by one or more oxa, aryloxyalkyl, alkoxyaryl and their halogen-substituted derivatives;
each of R50, R51and R52independently selected from the group comprising H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenylacyl, alkanity, aryloxy, aaltio, aminoalkyl;
m is an integer from 1 to 3;
and where at least two of the above R11groups contain at least two adjacent carbon atom directly attached to the nitrogen atoms, carbon atoms inposition relative to the nitrogen atom is substituted by hydroxy and at least one member selected from the group comprising: hydroxymethyl, alkoxymethyl, arcenciel, relaxometer and combinations thereof; and where, optionally, any two of R11, R12and R13merged to form a ring structure;
and their dimers, where these dimers formed by covalent attachment of the two compounds of the formula (I) via a linking group containing from 1 to 6 carbon atoms; and their physiological salts, provided that the molecular weight of the specified complexing agents does not exceed 2000.

47. Connection on p. 46, where the cations of these physiological salts are the sodium and N-methylglucamine.

 

Same patents:

The invention relates to a bleaching composition for bleaching textiles and suppression of absorption and adsorption stains or dyes for absorbing or adsorbing the substrate

The invention relates to macrocyclic metal complexes of ligands, used as bleach activators

The invention relates to new derivatives of carboxylic acids of General formula I containing heterocyclic ring

The invention relates to the object characterized in the claims, t

The invention relates to a method for producing TRANS-1,4,5,8-tetranitro-1,4,5,8-tetrasaccharide used in the synthesis of explosives, components of solid rocket fuels, gas generators (R. L. Willer, Atkinds R. L

The invention relates to the field of synthesis of new biologically active compounds

The invention relates to new diazepinones derivatives, method for their production and to their containing pharmaceutical compositions
The invention relates to a method for producing triethanolamine used in lubricating and cooling and hydraulic fluids, by reacting aqueous ammonia with ethylene oxide

The invention relates to the field of organic chemistry, namely, to a new method of producing 1,2-aminoalcohols

The invention relates to the technology of basic organic synthesis, namely to receive the ethanolamines, in particular triethanolamine
The invention relates to the production of Diethylenetriamine, which is used as a hardener for epoxy resins

The invention relates to the oil industry and is designed for corrosion protection of oil field equipment, namely, to a new, first synthesized mixture of aminopropanol, as a corrosion inhibitor
The invention relates to the pharmaceutical industry, specifically to medicines used for the prevention, mitigation or treatment of pathological conditions by destroying parasitic organisms through chemical effects on their physiology

The invention relates to the field of medicine and is suitable for treatment of infections of the upper and lower respiratory tract infections, septic conditions, mastitis, osteomyelitis, peritonitis other suppurative-inflammatory processes

The invention relates to the field of organic chemistry, namely to new biologically active compounds of class pyrazolylborate acids
The invention relates to medicine, specifically to means for treating purulent wounds, local wound infection and inflammatory diseases

The invention relates to a method for producing derivatives of imidazole of formula A, where R1represents a substituted heterocycle, R4is phenyl, optionally substituted, R2represents the алкилN3, -(CR10R20)nOR9further as stated in the description
The invention relates to medicine, namely to surgery, and for the prevention and treatment of purulent-inflammatory complications in the pre - and postoperative periods
The invention relates to medicine

The invention relates to a derivative of benzopyran-2-it formula I, where R1denotes a hydrogen atom, a hydroxyl radical, optionally substituted alkyl radical, optionally interrupted by oxygen atom, sulfur or nitrogen, CNS radical or a radical NRcRdX denotes an oxygen atom or a radical N-N(CH3)2or radical NOalc2where alc2denotes optionally substituted alkyl radical, optionally interrupted by oxygen atom, sulfur or nitrogen,2denotes a hydrogen atom or halogen atom, R3denotes a hydrogen atom, an alkyl radical or a halogen atom, R4denotes a radical NRgRh, optionally substituted aryl or heteroaryl radical, R5denotes a hydrogen atom or O-alkyl, R6denotes alkyl or CH2-O-alkyl, R7denotes a hydrogen atom or alkyl
Up!